Cambridge Cognition appoints Pfizer's Keir CEO
This article was originally published in Scrip
Executive Summary
UK developer of computerised neuropsychological tests for the pharmaceutical industry and research institutions, Cambridge Cognition, has appointed Ruth Keir CEO. Ms Keir was previously head of global strategic alliances at Pfizer, and was actively involved in the implementation of the Innovative Medicines Initiative. Cambridge Cognition has also hired Professor Wim Riedel, head of experimental psychopharmacology at Maastricht University in the Netherlands, as vice-president of science. Professor Riedel was previously global head of neuropsychology at GlaxoSmithKline.